This visit reviews your weight history, medical conditions, medications, past diet attempts, appetite patterns, activity level, metabolic risk factors, and goals
Key distinctions in the evidence: Tesamorelin: licensed in the US, narrowly indicated, established in HIV-related lipodystrophy, with effects that reverse on stopping treatment Retatrutide: investigational, broader metabolic potential, not yet approved anywhere globally Patients and clinicians should interpret early-phase data for retatrutide with appropriate caution
Can I take it long term
Clinical trial dosage results summary The dosage charts above are not arbitrary
Certain individuals may be at heightened risk of experiencing adverse effects from retatrutide, particularly with prolonged use
Currently, there are a lot of gray and black market options out there that have not been tested and thus lack quality and safety control